Tuning Reactivity of Platinum(II) Complexes

Endocr. Metab. Invest. Drugs, 1999, 4, 443; (c) Anormed Product Profile: ZD0473,
June 2001.
62 Y. Chen, Z. Guo, S. Parsons and P.J. Sadler, Chem. Eur. J., 1998, 4, 672.
63 (a) T. W. Sorenson, M. Eastman, Cancer Res., 1988, 48, 4484; (b) M. Eastman, In
Cisplatin: Chemistry and biochemistry of a leading anticancer drug, 1999, B.
Lippert, Ed. Wiley VCH, Weinheim, 111.
64 C. M. Giandomenico, M. J. Abrams, B. A. Murrer, J. F. Vollano, M. I. Rheinheimer, S.
B. Wyer, G. E. Bossard, and J. D. Higgins, Inorg. Chem., 1995, 34, 1015.
65 V. Kvardova, R. Hrstka, D. Walerych, P. Muller, E. Matoulkova, V. Hruskova, D.
Stelclova, P. Sova and B. Vojtesek, Molecular Cancer 2010, 9:147.
66 Y.-C. Lo, T-P, Ko, W-C, Su, T-L, Su and A. H.-J. Wang, J. Inorg. Biochem., 2009, 103,
1082.
67 H.-Ke. Liu and P. J. Sadler,Acc. Chem. Research, 2011, 44, 349.and cited references
therein.
68 G. Lowe, S. A. Ross, M. Probert and A. Cowley, Chem. Commun., 2001, 14, 1288.
69 G. Lowe, A.S. Droz, T. Vilaivan, G. W. Weaver, J. J. Park, J.M. Pratt, L. Tweedale and
L. R. Kelland, J. Med. Chem., 1999, 42, 3167.
70 K. Jennette, S. J. Lippard, G. Vassiliades and W. Bauer, Proc. Natl. Acad. Sci. U.S.A,
1974, 71, 3839.
71 M. Howe-Grant, K. C. Wu, W. R. Bauer and S. J. Lippard, Biochemistry, 1976, 15,
4339.
72 M. Casamento, G. E Arena, C. Lo Passo, I. Pernice, A. Romeo and L. Monsú Scolaro,
Inorg. Chim. Acta., 1998, 276, 242.
73 (a) D. Jaganyi, A. Hofmann and R. van Eldik, Angew. Chem., Int. Ed. 2001, 40, 1680;
(b) A. Hofmann, D. Jaganyi, O. Q. Munro, G. Leihr and R. van Eldik, Inorg. Chem.,
2003, 42, 1688; (c) D. Jaganyi and F. Tiba, Transition Met. Chem., 2003, 28, 803,
D. Jaganyi, D. Reddy, J. A. Gertenbach, A. Hofmann and R. van Eldik, J. Chem Soc.,
Dalton Trans. 2004, 299.
74 J. Reedijk, Proc. Natl. Acad. Sci. U.S.A., 2003, 3611-3616.
75 N. J. Wheate, and J. D. Collins, Curr. Med. Chem.-Anti-Cancer Agents, 2005, 5, 267.
24